Objectives-Patient-reported outcomes (PRO) help patients, caretakers, clinicians and policy makers make informed decisions regarding treatment effectiveness. Our objective was to assess the quality of PRO reporting and methodological strengths and weaknesses in randomized controlled trials (RCT) in bladder cancer.
Introduction
Bladder cancer is the 7 th most common cancer in men worldwide, with an estimated total of 429,793 new cases and 165,068 deaths in 2012 [1] . Bladder cancer is more common in the western world, and is the 6 th most common cancer in the United States, accounting for an estimated 74,690 new cases and 15,580 deaths in 2014 [2] . Approximately 30% of newly diagnosed patients will have muscle-invasive bladder cancer (MIBC), for which neoadjuvant chemotherapy and radical cystectomy with urinary diversion are considered the standard-of-care [3] . A subset of patients with non-muscle invasive bladder cancer (NMIBC) will progress to invasive disease while many others will have a protracted disease course that may include invasive monitoring and intravesical treatments [4] .
For any stage of bladder cancer, informed decision-making needs to consider objective outcome measures with a high level of evidence as well as the patient's values and experience [5] . It is increasingly recognized that patient-reported outcomes (PRO) help patients, caretakers, clinicians and policy makers make decisions regarding treatment effectiveness [6; 7] . However, previous systematic reviews have noted several weaknesses in PRO studies in bladder cancer, including retrospective study design and use of non-validated questionnaires [8; 9] . Further, reviews in other cancers have shown poor PRO reporting in randomized controlled trials (RCT) [10; 11] . Therefore, standards for reporting PRO in RCTs have recently been established [12; 13] . The objective of this review was to identify the number of RCTs in bladder cancer that have included PRO as an endpoint, and to assess the quality of PRO reporting from these studies.
Materials and Methods

Search strategy and identification of studies
An electronic, systematic literature search using Pubmed/Medline, the Cochrane Library, PsycINFO and PsychARTICLES was used to identify RCTs in bladder cancer with a PRO component from January 2004 to March 2014. Details of our search strategy used in other cancers have been previously described [10; 11; 14] . We limited our search to the last 10 years because a previous MEDLINE search of the literature from 1966 to January 2004 found no RCT evaluating PRO after radical cystectomy [9] . Relevant studies listed as references were also considered. 
Results
The systematic literature search yielded 1,682 records ( Figure 1 ). After screening records, 58 full-text articles were assessed for eligibility of which 48 articles were excluded for being non-randomized (n=27), not including PRO (n=14), mixed sample (n=1), screening study (n=4), and non-English language (n=2). The result was 10 articles on 9 RCTs that met our study criteria enrolling 1,237 patients [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] . A summary of the main clinical results and PRO findings are presented in Table 1 .
All 9 RCTs were performed in patients with non-metastatic disease: 5 in patients with NMIBC and 4 in patients with MIBC. In 5 RCTs, a PRO was the primary endpoint. The level of PRO reporting based on ISOQOL recommendations is presented in the Supplement Table. Although 8 RCTs identified PRO as an endpoint in the abstract, only 2 stated a PRO hypothesis in the introduction. Seven RCTs did not report the mode of PRO administration or the methods of collecting data. A major limitation was the handling of missing data. None of the studies addressed the statistical approaches for missing data and only 1 stated the extent of, or the reasons for, missing data.
Four studies used versions of the EORTC instruments, and 3 studies used a bladder-specific instrument. However, 4 studies did not provide the rationale for choice of PRO instrument or evidence of PRO instrument validity.
Of the 5 RCT that used PRO as the primary endpoint, 3 described the limitations, generalizability and clinical significance of the PRO. All 5 interpreted the PRO in the discussion and discussed PRO in the context of other trial endpoints.
Two trials in patients undergoing radical cystectomy reported PRO differences. In a comparison of general plus epidural anesthesia versus general anesthesia alone, general plus epidural anesthesia was associated with improved pain control at all measured time points within 24 hours after surgery [21] . In a comparison of an early recovery after surgery protocol versus a conservative recovery regimen, patients treated with the early recovery protocol reported more favorable functioning and symptom scores on several EORTC measures on post-operative days 3, 7 and at discharge [18] .
One study examined radiotherapy with and without chemotherapy for bladder-sparing treatment of MIBC. While this study met our inclusion criteria as a RCT of an intervention measuring PRO, this study did not report the instrument used, method or schedule of data collection, or PRO results [17] .
Three of the 5 trials in NMIBC patients reported PRO differences. During transurethral resection of bladder tumors, fewer patients receiving spinal anesthesia with bupivacaine reported moderate or severe pain compared to patients receiving sufentanil [20] . However, bupivacaine was associated with intense motor blockade and longer time to recovery room discharge. A trial of oral anticholinergic therapy versus placebo during induction bacillus Calmette-Guerin (BCG) therapy reported more urinary and non-urinary symptoms with anticholinergic therapy with no clinical benefit [23] . In a comparison of gemcitabine versus one-third dose BCG for maintenance therapy, gemcitabine was associated with better functioning and symptoms on univariate but not multivariate analysis [16] .
Discussion
Although bladder cancer is one of the most common cancers worldwide, there is paucity of evidence-based PRO from clinical trials. In the last decade, fewer than 1,300 bladder cancer patients were enrolled in a RCT evaluating PRO. Notably, 2 of these 9 studies focused primarily on anesthesia and peri-operative pain control rather than bladder cancer outcomes.
In contrast, a large number of RCTs with a PRO component have been conducted in prostate and gynecological cancers during a similar time period [10; 11] . Whereas we found no RCT in bladder cancer with robust PRO, in prostate and gynecological cancers the rate of highquality PRO reporting likely to impact clinical decision-making was found to be 20% and 32%, respectively.
Historically, there have been few validated instruments in NMIBC or MIBC [8] . The EORTC QLQ-NMIBC24 was recently validated for use in clinical trials for intermediate and high-risk NMIBC [25] . This instrument was used by 1 of the 5 RCT in NMIBC we evaluated, while the other RCT used either ad hoc or generic cancer questionnaires. In MIBC, new instruments for evaluating the effects of radical cystectomy have recently been validated, including the Bladder Cancer Index and the Functional Assessment of Cancer Therapy-Vanderbilt Cystectomy Index (FACT-VCI) [26; 27] . Only 1 MIBC study we evaluated used a bladder-specific questionnaire. Four of the 9 studies evaluated did not provide the rationale for PRO instrument used and 4 did not provide the validity or reliability of the instrument used. The purpose of disease-specific, validated questionnaires is to capture PRO data meaningful to stakeholders for clinical decision-making. We believe that the dissemination of newer instruments will improve the quality of PRO reporting.
Much of the interest in PRO in bladder cancer has been comparing outcomes by urinary diversion type: ileal conduit, continent cutaneous or orthotopic neobladder. Understandably, there are no RCT comparing these diversions, and therefore, few RCT in MIBC. Prior to January 2004, there were no RCT evaluating PRO after radical cystectomy [9] . Of the 3 RCT we found in patients undergoing radical cystectomy, 1 examined techniques in orthotopic neobladder creation and 2 examined post-operative recovery and pain control.
Some of the weaknesses of PRO reporting in bladder cancer we found have previously been described [8; 9] . In the current review, only 3 studies reported baseline PRO data. Four studies did not provide the rationale for choice of the PRO instrument or the psychometric properties.
As in prostate and gynecological cancers, one of the main weaknesses of PRO reporting was in the handling of missing data. [10; 11] Missing data leads to reduced power and can be a significant source of bias. Missing data in PRO studies are often not random and can be associated with the outcome of interest. For example, patients completing a PRO survey after surgery may have considerable demographic and clinical differences compared to patients who chose not to complete the survey. The extent of missing data and the statistical handling of this data are, therefore, critical to understanding the generalizability of PRO findings.
This study highlights the current weaknesses of PRO reporting in bladder cancer RCTs. In contrast to previous systematic reviews, we used a formal, objective approach to evaluating PRO reporting in the bladder cancer literature. As has been demonstrated in similar reviews in prostate and gynecological cancers, high-quality PRO reporting can facilitate clinical decision-making and approval of beneficial interventions. [10; 11] When designing RCTs in bladder cancer, investigators should recognize the importance of including valid and reliable PROs in the trial protocol and the necessity for detailing the methodology of PRO assessment.
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